CN1679548A - 一种含洛伐他汀的组合物及其用途 - Google Patents
一种含洛伐他汀的组合物及其用途 Download PDFInfo
- Publication number
- CN1679548A CN1679548A CN 200510049300 CN200510049300A CN1679548A CN 1679548 A CN1679548 A CN 1679548A CN 200510049300 CN200510049300 CN 200510049300 CN 200510049300 A CN200510049300 A CN 200510049300A CN 1679548 A CN1679548 A CN 1679548A
- Authority
- CN
- China
- Prior art keywords
- lovastatin
- compositions
- preparation
- pantethine
- blood
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- PCZOHLXUXFIOCF-BXMDZJJMSA-N lovastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 PCZOHLXUXFIOCF-BXMDZJJMSA-N 0.000 title claims abstract description 52
- PCZOHLXUXFIOCF-UHFFFAOYSA-N Monacolin X Natural products C12C(OC(=O)C(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 PCZOHLXUXFIOCF-UHFFFAOYSA-N 0.000 title claims abstract description 49
- 229960004844 lovastatin Drugs 0.000 title claims abstract description 49
- QLJODMDSTUBWDW-UHFFFAOYSA-N lovastatin hydroxy acid Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(C)C=C21 QLJODMDSTUBWDW-UHFFFAOYSA-N 0.000 title claims abstract description 49
- 239000000203 mixture Substances 0.000 title claims abstract description 48
- 210000004369 blood Anatomy 0.000 claims abstract description 22
- 239000008280 blood Substances 0.000 claims abstract description 22
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims abstract description 16
- 239000003814 drug Substances 0.000 claims abstract description 14
- 229930003944 flavone Natural products 0.000 claims abstract description 10
- 235000011949 flavones Nutrition 0.000 claims abstract description 10
- 235000012000 cholesterol Nutrition 0.000 claims abstract description 6
- 239000000654 additive Substances 0.000 claims abstract description 4
- 230000000996 additive effect Effects 0.000 claims abstract description 4
- DJWYOLJPSHDSAL-ROUUACIJSA-N pantethine Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSSCCNC(=O)CCNC(=O)[C@H](O)C(C)(C)CO DJWYOLJPSHDSAL-ROUUACIJSA-N 0.000 claims description 34
- DJWYOLJPSHDSAL-UHFFFAOYSA-N Pantethine Natural products OCC(C)(C)C(O)C(=O)NCCC(=O)NCCSSCCNC(=O)CCNC(=O)C(O)C(C)(C)CO DJWYOLJPSHDSAL-UHFFFAOYSA-N 0.000 claims description 33
- 235000008975 pantethine Nutrition 0.000 claims description 33
- 239000011581 pantethine Substances 0.000 claims description 33
- 229960000903 pantethine Drugs 0.000 claims description 33
- 238000002360 preparation method Methods 0.000 claims description 32
- 235000010469 Glycine max Nutrition 0.000 claims description 17
- 244000068988 Glycine max Species 0.000 claims description 17
- GOMNOOKGLZYEJT-UHFFFAOYSA-N isoflavone Chemical compound C=1OC2=CC=CC=C2C(=O)C=1C1=CC=CC=C1 GOMNOOKGLZYEJT-UHFFFAOYSA-N 0.000 claims description 17
- CJWQYWQDLBZGPD-UHFFFAOYSA-N isoflavone Natural products C1=C(OC)C(OC)=CC(OC)=C1C1=COC2=C(C=CC(C)(C)O3)C3=C(OC)C=C2C1=O CJWQYWQDLBZGPD-UHFFFAOYSA-N 0.000 claims description 17
- 235000008696 isoflavones Nutrition 0.000 claims description 17
- 150000002632 lipids Chemical class 0.000 claims description 11
- 235000011201 Ginkgo Nutrition 0.000 claims description 9
- 235000008100 Ginkgo biloba Nutrition 0.000 claims description 9
- 150000002213 flavones Chemical class 0.000 claims description 9
- 229930003935 flavonoid Natural products 0.000 claims description 9
- 150000002215 flavonoids Chemical class 0.000 claims description 9
- 235000017173 flavonoids Nutrition 0.000 claims description 9
- 239000007788 liquid Substances 0.000 claims description 9
- 239000007787 solid Substances 0.000 claims description 5
- 239000002552 dosage form Substances 0.000 claims 2
- 244000194101 Ginkgo biloba Species 0.000 claims 1
- -1 panthethine Natural products 0.000 abstract description 8
- 201000005577 familial hyperlipidemia Diseases 0.000 abstract description 4
- 229940079593 drug Drugs 0.000 abstract description 3
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 abstract 1
- 230000003247 decreasing effect Effects 0.000 abstract 1
- 150000002212 flavone derivatives Chemical class 0.000 abstract 1
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 abstract 1
- 108010007622 LDL Lipoproteins Proteins 0.000 description 15
- 102000007330 LDL Lipoproteins Human genes 0.000 description 15
- 230000000694 effects Effects 0.000 description 12
- 238000000034 method Methods 0.000 description 11
- 241000218628 Ginkgo Species 0.000 description 8
- 239000002775 capsule Substances 0.000 description 7
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 7
- 108010010234 HDL Lipoproteins Proteins 0.000 description 6
- 102000015779 HDL Lipoproteins Human genes 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 4
- SQGLUEWZRKIEGS-UHFFFAOYSA-N Ginkgetin Natural products C1=CC(OC)=CC=C1C1=CC(=O)C2=C(O)C=C(OC)C(C=3C(=CC=C(C=3)C=3OC4=CC(O)=CC(O)=C4C(=O)C=3)O)=C2O1 SQGLUEWZRKIEGS-UHFFFAOYSA-N 0.000 description 4
- 229930045534 Me ester-Cyclohexaneundecanoic acid Natural products 0.000 description 4
- 241000700159 Rattus Species 0.000 description 4
- 108010062497 VLDL Lipoproteins Proteins 0.000 description 4
- 239000008187 granular material Substances 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 239000011777 magnesium Substances 0.000 description 3
- 229910052749 magnesium Inorganic materials 0.000 description 3
- 235000019359 magnesium stearate Nutrition 0.000 description 3
- 239000002207 metabolite Substances 0.000 description 3
- 239000002547 new drug Substances 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 108700022737 rat Fat1 Proteins 0.000 description 3
- 102100036475 Alanine aminotransferase 1 Human genes 0.000 description 2
- 108010082126 Alanine transaminase Proteins 0.000 description 2
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 201000002481 Myositis Diseases 0.000 description 2
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 239000012467 final product Substances 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- AIFCFBUSLAEIBR-UHFFFAOYSA-N ginkgetin Chemical compound C=1C(OC)=CC(O)=C(C(C=2)=O)C=1OC=2C(C=1)=CC=C(OC)C=1C1=C(O)C=C(O)C(C(C=2)=O)=C1OC=2C1=CC=C(O)C=C1 AIFCFBUSLAEIBR-UHFFFAOYSA-N 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 229940055726 pantothenic acid Drugs 0.000 description 2
- 235000019161 pantothenic acid Nutrition 0.000 description 2
- 239000011713 pantothenic acid Substances 0.000 description 2
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 2
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 2
- 229940068968 polysorbate 80 Drugs 0.000 description 2
- 229920000053 polysorbate 80 Polymers 0.000 description 2
- 210000000582 semen Anatomy 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- ZEMPKEQAKRGZGQ-AAKVHIHISA-N 2,3-bis[[(z)-12-hydroxyoctadec-9-enoyl]oxy]propyl (z)-12-hydroxyoctadec-9-enoate Chemical compound CCCCCCC(O)C\C=C/CCCCCCCC(=O)OCC(OC(=O)CCCCCCC\C=C/CC(O)CCCCCC)COC(=O)CCCCCCC\C=C/CC(O)CCCCCC ZEMPKEQAKRGZGQ-AAKVHIHISA-N 0.000 description 1
- 208000009304 Acute Kidney Injury Diseases 0.000 description 1
- XUKUURHRXDUEBC-KAYWLYCHSA-N Atorvastatin Chemical compound C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-KAYWLYCHSA-N 0.000 description 1
- XUKUURHRXDUEBC-UHFFFAOYSA-N Atorvastatin Natural products C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CCC(O)CC(O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-UHFFFAOYSA-N 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Natural products CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 1
- RGJOEKWQDUBAIZ-IBOSZNHHSA-N CoASH Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCS)O[C@H]1N1C2=NC=NC(N)=C2N=C1 RGJOEKWQDUBAIZ-IBOSZNHHSA-N 0.000 description 1
- 208000031288 Combined hyperlipidaemia Diseases 0.000 description 1
- 102000004420 Creatine Kinase Human genes 0.000 description 1
- 108010042126 Creatine kinase Proteins 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- 208000035150 Hypercholesterolemia Diseases 0.000 description 1
- 229920002752 Konjac Polymers 0.000 description 1
- 108010028554 LDL Cholesterol Proteins 0.000 description 1
- WSMYVTOQOOLQHP-UHFFFAOYSA-N Malondialdehyde Chemical compound O=CCC=O WSMYVTOQOOLQHP-UHFFFAOYSA-N 0.000 description 1
- 208000000112 Myalgia Diseases 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 229940123934 Reductase inhibitor Drugs 0.000 description 1
- 208000033626 Renal failure acute Diseases 0.000 description 1
- 206010039020 Rhabdomyolysis Diseases 0.000 description 1
- 208000034189 Sclerosis Diseases 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 102000019197 Superoxide Dismutase Human genes 0.000 description 1
- 108010012715 Superoxide dismutase Proteins 0.000 description 1
- 108090000340 Transaminases Proteins 0.000 description 1
- UNLRVSBRNJYNHN-UHFFFAOYSA-N [cyano-(3-phenoxyphenyl)methyl] 2-(4-chlorophenyl)-3-methylbutanoate;dimethoxy-(4-nitrophenoxy)-sulfanylidene-$l^{5}-phosphane Chemical compound COP(=S)(OC)OC1=CC=C([N+]([O-])=O)C=C1.C=1C=C(Cl)C=CC=1C(C(C)C)C(=O)OC(C#N)C(C=1)=CC=CC=1OC1=CC=CC=C1 UNLRVSBRNJYNHN-UHFFFAOYSA-N 0.000 description 1
- 206010000059 abdominal discomfort Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 201000011040 acute kidney failure Diseases 0.000 description 1
- 208000012998 acute renal failure Diseases 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 239000003524 antilipemic agent Substances 0.000 description 1
- 230000003143 atherosclerotic effect Effects 0.000 description 1
- 229960005370 atorvastatin Drugs 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- RGJOEKWQDUBAIZ-UHFFFAOYSA-N coenzime A Natural products OC1C(OP(O)(O)=O)C(COP(O)(=O)OP(O)(=O)OCC(C)(C)C(O)C(=O)NCCC(=O)NCCS)OC1N1C2=NC=NC(N)=C2N=C1 RGJOEKWQDUBAIZ-UHFFFAOYSA-N 0.000 description 1
- 239000005516 coenzyme A Substances 0.000 description 1
- 229940093530 coenzyme a Drugs 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- KDTSHFARGAKYJN-UHFFFAOYSA-N dephosphocoenzyme A Natural products OC1C(O)C(COP(O)(=O)OP(O)(=O)OCC(C)(C)C(O)C(=O)NCCC(=O)NCCS)OC1N1C2=NC=NC(N)=C2N=C1 KDTSHFARGAKYJN-UHFFFAOYSA-N 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 229940000406 drug candidate Drugs 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 210000003725 endotheliocyte Anatomy 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- BEGBSFPALGFMJI-UHFFFAOYSA-N ethene;sodium Chemical group [Na].C=C BEGBSFPALGFMJI-UHFFFAOYSA-N 0.000 description 1
- 239000003777 experimental drug Substances 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 238000010579 first pass effect Methods 0.000 description 1
- 210000000497 foam cell Anatomy 0.000 description 1
- SYKWLIJQEHRDNH-KRPIADGTSA-N glutaryl-coa Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)C(O)C(=O)NCCC(=O)NCCSC(=O)CCCC(O)=O)O[C@H]1N1C2=NC=NC(N)=C2N=C1 SYKWLIJQEHRDNH-KRPIADGTSA-N 0.000 description 1
- 231100000304 hepatotoxicity Toxicity 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000037356 lipid metabolism Effects 0.000 description 1
- 230000007056 liver toxicity Effects 0.000 description 1
- 238000011866 long-term treatment Methods 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 108010030696 low density lipoprotein triglyceride Proteins 0.000 description 1
- 229940118019 malondialdehyde Drugs 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 235000021590 normal diet Nutrition 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000001253 polyvinylpolypyrrolidone Substances 0.000 description 1
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 description 1
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000012797 qualification Methods 0.000 description 1
- 238000011552 rat model Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 235000015170 shellfish Nutrition 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 235000010234 sodium benzoate Nutrition 0.000 description 1
- 239000004299 sodium benzoate Substances 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 229960002920 sorbitol Drugs 0.000 description 1
- 235000003687 soy isoflavones Nutrition 0.000 description 1
- 235000013599 spices Nutrition 0.000 description 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 206010043554 thrombocytopenia Diseases 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 102000014898 transaminase activity proteins Human genes 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 238000011282 treatment Methods 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
| 4片中(1400mg) | 4片中(1400mg) | 4片中(1400mg) | |
| 洛伐他汀 | 20mg | 20mg | 20mg |
| 泛硫乙胺 | 550mg | 500mg | 500mg |
| 大豆异黄酮 | - | 225mg | - |
| 银杏黄酮 | - | - | 225mg |
| 结晶纤维素 | 170mg | 120mg | 120mg |
| 偏硅酸铝酸镁 | 60mg | - | - |
| 蔗糖脂肪酸酯 | 200mg | 140mg | 140mg |
| 羟丙基纤维素 | 48mg | 48mg | 48mg |
| 硬脂酸镁 | 24mg | 24mg | 24mg |
| 交联聚维酮 | 48mg | 48mg | 48mg |
| 乳糖 | 适量 | 适量 | 适量 |
| 4包中(5g) | 4包中(5g) | 4包中(5g) | |
| 洛伐他汀 | 20mg | 20mg | 20mg |
| 泛硫乙胺 | 1100mg | 1000mg | 1000mg |
| 大豆异黄酮 | - | 300mg | - |
| 银杏总黄酮 | - | - | 300mg |
| 精制蔗糖 | 1650mg | 1600mg | 1600mg |
| 淀粉 | 1300mg | 1200mg | 1200mg |
| 聚山梨醇酯80 | - | 48mg | 48mg |
| 偏硅酸铝酸镁 | 50mg | - | - |
| 硬脂酸镁 | 24mg | 24mg | 24mg |
| 乳糖 | 适量 | 适量 | 适量 |
| 4胶囊中 | 4胶囊中 | 4胶囊中 | |
| 洛伐他汀 | 20mg | 20mg | 20mg |
| 泛硫乙胺 | 550mg | 500mg | 500mg |
| 大豆异黄酮 | - | 300mg | - |
| 银杏总黄酮 | - | - | 300mg |
| 淀粉 | 1210mg | 960mg | 960mg |
| 聚山梨醇酯80 | - | 48mg | 48mg |
| 偏硅酸铝酸镁 | 50mg | - | - |
| 硬脂酸镁 | 24mg | 24mg | 24mg |
| 乳糖 | 适量 | 适量 | 适量 |
| 100mL中 | 100mL中 | 100mL中 | |
| 洛伐他汀 | 20mg | 20mg | 20mg |
| 泛硫乙胺 | 550mg | 500mg | 500mg |
| 大豆异黄酮 | - | 300mg | - |
| 银杏总黄酮 | - | - | 300mg |
| D-山梨醇液 | 6g | 6g | 6g |
| 蜂蜜 | 8g | 8g | 8g |
| 乙二胺四乙酸钠 | 20mg | 20mg | 20mg |
| 乙醇 | 2ml | 2mL | 2mL |
| 硬脂酸聚氧乙烯硬化 | 100mg | 100mg | 100mg |
| 蓖麻油60 | - | - | - |
| 苯甲酸钠 | 60mg | 60mg | 60mg |
| 香料 | 微量 | 微量 | 微量 |
| 蒸馏水 | 适量 | 适量 | 适量 |
| 组别 | 血清脂质升高值(mg/dl) | 毒性(U/L) | |||||||
| 总胆固醇 | 甘油三脂 | 高密度脂蛋白 | 低密度脂蛋白 | 极低密度脂蛋白 | 总胆固醇/高密度脂蛋白 | 丙氨酸氨基转移酶(ALT) | 肌酸激酶 | 天冬氨酸氨基转移酶酶(AST) | |
| 溶剂 | 204±42 | 61±20 | 12±9 | 180±45 | 21±17 | 2.23±0.72 | 42±9 | 609±150 | 175±35 |
| 洛伐他汀7.5mg/kg | 177±25 | 62±17 | 17±15 | 168±23 | 23±13 | 2.23±0.59 | 62±28* | 611±203 | 174±32 |
| 泛硫乙胺67.5mg/kg | 198±88 | 63±26 | 21±8* | 174±58 | 26±13 | 1.94±0.76 | 46±9# | 633±234 | 194±35 |
| 洛伐他汀 | 166±97 | 63±29 | 19±13 | 154±62 | 15±14 | 1.99±0.81 | 56±28 | 629±162 | 183±27 |
| 7.5mg/kg+泛硫乙胺67.5mg/kg | |
| 洛伐他汀7.5mg/kg+泛硫乙胺67.5mg/kg+银杏总黄酮30mg/kg | 49±126±35*# 24±11* 127±29*# 11±9*# 2.62±0.83 41±13# 606±183 188±4820*# |
| 洛他汀7.5mg/kg+泛硫乙胺67.5mg/kg+大豆异黄酮30mg/kg | 118± 47±24±7* 125±20*# 8±8*# 1.54±0.31# 39±11# 602±133 177±3227*## 18*# |
Claims (8)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB200510049300XA CN1332657C (zh) | 2005-01-31 | 2005-01-31 | 一种含洛伐他汀的组合物及其用途 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB200510049300XA CN1332657C (zh) | 2005-01-31 | 2005-01-31 | 一种含洛伐他汀的组合物及其用途 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1679548A true CN1679548A (zh) | 2005-10-12 |
| CN1332657C CN1332657C (zh) | 2007-08-22 |
Family
ID=35066571
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB200510049300XA Expired - Fee Related CN1332657C (zh) | 2005-01-31 | 2005-01-31 | 一种含洛伐他汀的组合物及其用途 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1332657C (zh) |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1141092C (zh) * | 2001-01-19 | 2004-03-10 | 郭兴华 | 一种防治骨质疏松、癌症和降血脂组合物及其应用 |
| BR0312426A (pt) * | 2002-07-03 | 2005-12-06 | Esperion Therapeutics Inc | Composição farmacêutica, métodos para tratar, prevenir ou controlar um colesterol, dislipidemia ou distúrbio relacionado, para reduzir ou evitar um efeito adverso associado com monoterapia de pantetina e para reduzir ou evitar um efeito adverso associado com monoterapia de segundo agente ativo, e, kit |
| CN100496563C (zh) * | 2003-10-27 | 2009-06-10 | 济南孟氏生物科技研究所有限公司 | 一种防治高脂血症、动脉粥样硬化及相关疾病的天然产物组合物 |
-
2005
- 2005-01-31 CN CNB200510049300XA patent/CN1332657C/zh not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| CN1332657C (zh) | 2007-08-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP2488180A2 (en) | Pharmaceutical compositions for the treatment/prophylaxis of non-alcoholic fatty liver disease | |
| US6673831B1 (en) | Combination therapy for reducing the risks associated with cardiovascular disease | |
| KR20010093845A (ko) | 피브레이트와 세리바스타틴의 복합제제 | |
| EP3880203A1 (en) | A method for treating pulmonary arterial hypertension and associated pulmonary arterial hypertension | |
| RU2003122061A (ru) | Антиатеросклеротическая композиция, содержащая каротиноиды, и способ ингибирования окисления липопротеина низкой плотности (ldl) | |
| CN103239439B (zh) | 用于治疗高血脂及动脉粥样硬化的组合物及其用途 | |
| CN104840963B (zh) | 含脂蛋白相关性磷脂酶a2抑制剂的药物组合物及应用 | |
| NZ501844A (en) | Alkanoyl L-carnitine in combination with a statin (simvastatin, lovastatin, provastatin or fluvastatin) for treating abnormal lipid metabolism disorders | |
| US20110117070A1 (en) | Compositions and methods for treating headache | |
| CN1274302C (zh) | 含阿伐他汀的降血脂组合物及其用途 | |
| CN1679548A (zh) | 一种含洛伐他汀的组合物及其用途 | |
| CN101884643A (zh) | 含有吡格列酮和肝素或低分子肝素的药物组合物的新用途 | |
| WO2009100245A1 (en) | Low dose hmg-coa reductase inhibitor with reduced side effects | |
| CN1679547A (zh) | 一种调血脂药物组合物及其用途 | |
| KR100725263B1 (ko) | HMG-CoA 리덕타제 억제제 및 카르니틴을 포함하는 항지질혈성 복합제 | |
| CN113134086B (zh) | 一种降血脂的药物组合物 | |
| JP4741581B2 (ja) | 高脂血症治療の組成物 | |
| WO2015066784A1 (en) | Pharmaceutical composition, oral pharmaceutical form, capsule, bilayer tablet, uses, method of treating hypercholesterolemia, hypertriglyceridemia and/or mixed dyslipidemia, and method of preventing atherosclerosis, diabetes or secondary prevention of other cardiovascular diseases | |
| CN100566716C (zh) | 治疗高血脂症的组合物 | |
| CN113133997B (zh) | 一种含小檗碱的药物组合物及其用途 | |
| CN102416015B (zh) | 一种含他汀类药物的组合物及其用途 | |
| CN100579567C (zh) | 一种中药制剂在制备预防冠心病药物中的用途 | |
| KR100615532B1 (ko) | 잠분을 함유하는 신경안정용 약제학적 조성물 | |
| RU2329051C1 (ru) | Композиция, обладающая гиполипидемической и гепатопротекторной активностью | |
| RU2500399C2 (ru) | Комбинированное анальгезирующее и спазмолитическое средство |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| ASS | Succession or assignment of patent right |
Owner name: ZHEJIANG HANGZHOU XINFU PHARMACEUTICAL CO., LTD. Free format text: FORMER OWNER: XINFU PHARMACEUTICAL IND CO., LTD., HANGZHOU Effective date: 20080222 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20080222 Address after: Ling'an Economic Development Zone, Zhejiang Patentee after: ZHEJIANG HANGZHOU XINFU PHARMACEUTICAL Co.,Ltd. Address before: Economic Development Zone, Lin'an City, Zhejiang Province (Qingshanhu Street) Post code: 311305 Patentee before: ZHEJIANG HANGZHOU XINFU PHARMACEUTICAL Co.,Ltd. |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| C56 | Change in the name or address of the patentee | ||
| CP01 | Change in the name or title of a patent holder |
Address after: 311300 Ling'an Economic Development Zone, Zhejiang Patentee after: YIFAN XINFU PHARMACEUTICAL Co.,Ltd. Address before: 311300 Ling'an Economic Development Zone, Zhejiang Patentee before: ZHEJIANG HANGZHOU XINFU PHARMACEUTICAL Co.,Ltd. |
|
| TR01 | Transfer of patent right |
Effective date of registration: 20160720 Address after: Hangzhou City, Zhejiang province 311300 Ling'an City Kam South Street No. 9 Gua fan Patentee after: HANGZHOU XINFU SCIENCE & TECHNOLOGY Co.,Ltd. Address before: 311300 Ling'an Economic Development Zone, Zhejiang Patentee before: YIFAN XINFU PHARMACEUTICAL Co.,Ltd. |
|
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20070822 Termination date: 20210131 |
|
| CF01 | Termination of patent right due to non-payment of annual fee |